Author
Listed:
- Omar O. Abudayyeh
(Broad Institute of MIT and Harvard
McGovern Institute for Brain Research at MIT
Massachusetts Institute of Technology
Massachusetts Institute of Technology)
- Jonathan S. Gootenberg
(Broad Institute of MIT and Harvard
McGovern Institute for Brain Research at MIT
Massachusetts Institute of Technology
Massachusetts Institute of Technology)
- Patrick Essletzbichler
(Broad Institute of MIT and Harvard
McGovern Institute for Brain Research at MIT
Massachusetts Institute of Technology
Massachusetts Institute of Technology)
- Shuo Han
(Biology, and Chemistry, Stanford University)
- Julia Joung
(Broad Institute of MIT and Harvard
McGovern Institute for Brain Research at MIT
Massachusetts Institute of Technology
Massachusetts Institute of Technology)
- Joseph J. Belanto
(Cell Biology and Development, University of Minnesota
Center for Genome Engineering, University of Minnesota)
- Vanessa Verdine
(Broad Institute of MIT and Harvard
McGovern Institute for Brain Research at MIT
Massachusetts Institute of Technology
Massachusetts Institute of Technology)
- David B. T. Cox
(Broad Institute of MIT and Harvard
McGovern Institute for Brain Research at MIT
Massachusetts Institute of Technology
Massachusetts Institute of Technology)
- Max J. Kellner
(Broad Institute of MIT and Harvard)
- Aviv Regev
(Broad Institute of MIT and Harvard
Massachusetts Institute of Technology)
- Eric S. Lander
(Broad Institute of MIT and Harvard
Harvard Medical School
Massachusetts Institute of Technology)
- Daniel F. Voytas
(Cell Biology and Development, University of Minnesota
Center for Genome Engineering, University of Minnesota)
- Alice Y. Ting
(Biology, and Chemistry, Stanford University)
- Feng Zhang
(Broad Institute of MIT and Harvard
McGovern Institute for Brain Research at MIT
Massachusetts Institute of Technology
Massachusetts Institute of Technology)
Abstract
The class 2 type VI RNA-guided RNA-targeting CRISPR–Cas effector Cas13 can be engineered for RNA knockdown and binding, expanding the CRISPR toolset with a flexible platform for studying RNA in mammalian cells and therapeutic development.
Suggested Citation
Omar O. Abudayyeh & Jonathan S. Gootenberg & Patrick Essletzbichler & Shuo Han & Julia Joung & Joseph J. Belanto & Vanessa Verdine & David B. T. Cox & Max J. Kellner & Aviv Regev & Eric S. Lander & Da, 2017.
"RNA targeting with CRISPR–Cas13,"
Nature, Nature, vol. 550(7675), pages 280-284, October.
Handle:
RePEc:nat:nature:v:550:y:2017:i:7675:d:10.1038_nature24049
DOI: 10.1038/nature24049
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:550:y:2017:i:7675:d:10.1038_nature24049. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.